ENOV Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -10.02% compared to Enovis's net margin of 12.62%. Enovis's return on equity of -26.77% beat Globus Medical's return on equity of 4.59%.

Enovis has a consensus price target of $56.30, signalling upside risk potential of 84.35%. On the other hand Globus Medical has an analysts' consensus of $85.91 which suggests that it could grow by 51.76%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

Enovis has a beta of 1.494, which suggesting that the stock is 49.355% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.307%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are smaller than Globus Medical quarterly revenues of $598.1M. Enovis's net income of -$56M is lower than Globus Medical's net income of $75.5M. Notably, Enovis's price-to-earnings ratio is -- while Globus Medical's PE ratio is 42.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.79x versus 3.13x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -10.02% compared to Enovis's net margin of -6.61%. Enovis's return on equity of -26.77% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Enovis has a consensus price target of $56.30, signalling upside risk potential of 84.35%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 33.27%. Given that Enovis has higher upside potential than Integra Lifesciences Holdings, analysts believe Enovis is more attractive than Integra Lifesciences Holdings.

Enovis has a beta of 1.494, which suggesting that the stock is 49.355% more volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.152, suggesting its more volatile than the S&P 500 by 15.175%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are larger than Integra Lifesciences Holdings quarterly revenues of $382.7M. Enovis's net income of -$56M is lower than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Enovis's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.79x versus 0.57x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of -10.02% compared to Enovis's net margin of -2.56%. Enovis's return on equity of -26.77% beat ICU Medical's return on equity of -4.64%.

Enovis has a consensus price target of $56.30, signalling upside risk potential of 84.35%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 49.16%. Given that Enovis has higher upside potential than ICU Medical, analysts believe Enovis is more attractive than ICU Medical.

Enovis has a beta of 1.494, which suggesting that the stock is 49.355% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 13.002%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are smaller than ICU Medical quarterly revenues of $604.7M. Enovis's net income of -$56M is lower than ICU Medical's net income of -$15.5M. Notably, Enovis's price-to-earnings ratio is -- while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.79x versus 1.26x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -10.02% compared to Enovis's net margin of 0.18%. Enovis's return on equity of -26.77% beat Xtant Medical Holdings's return on equity of -26.62%.

Enovis has a consensus price target of $56.30, signalling upside risk potential of 84.35%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than Enovis, analysts believe Xtant Medical Holdings is more attractive than Enovis.

Enovis has a beta of 1.494, which suggesting that the stock is 49.355% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Enovis's net income of -$56M is lower than Xtant Medical Holdings's net income of $58K. Notably, Enovis's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.79x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.